Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Johnson & Johnson — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.35, while Johnson & Johnson trades at $249.49 (market cap $598.96B). The key difference: Johnson & Johnson pays a 2.15% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | JNJ | |
|---|---|---|
52-Week High | $97.99 | $267.24 |
52-Week Low | $93.11 | $164.36 |
Market Cap | — | $598.96B |
Volume | — | 6,156,228 |
Sector | — | Health |
Enterprise Value | — | $631.90B |
Dividend Yield | — | 2.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF (iShares 7-10 Year Treasury Bond ETF) trades at $93.54, down 0.32% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 58.33, while bond market uncertainty persists amid Federal Reserve policy speculation. Recent dividend payments of $0.31-$0.32 reflect steady income distribution to shareholders.
The outlook remains cautious as bond ETFs face pressure from potential rate hikes and inflation concerns. Investment opportunity lies in Treasury exposure for portfolio diversification, though risks include interest rate sensitivity and macroeconomic volatility affecting bond valuations.
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
